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Abstract. With the advent of deep generative models in computational
chemistry, in silico anticancer drug design has undergone an unprecedented
transformation. While state-of-the-art deep learning approaches have
shown potential in generating compounds with desired chemical properties,
they disregard the genetic profile and properties of the target disease. Here,
we introduce the first generative model capable of tailoring anticancer
compounds for a specific biomolecular profile. Using a RL framework,
the transcriptomic profiles of cancer cells are used as a context for the
generation of candidate molecules. Our molecule generator combines two
separately pretrained variational autoencoders (VAEs) – the first VAE
encodes transcriptomic profiles into a smooth, latent space which in turn
is used to condition a second VAE to generate novel molecular structures
on the given transcriptomic profile. The generative process is optimized
through PaccMann, a previously developed drug sensitivity prediction
model, to obtain effective anticancer compounds for the given context
(i.e., transcriptomic profile).
We demonstrate how the molecule generation can be biased towards
compounds with high predicted inhibitory effect against individual cell
lines or specific cancer sites. We verify our approach by investigating
candidate drugs generated against specific cancer types and find the
highest structural similarity to existing compounds with known efficacy
against these cancer types. We envision our approach to transform in silico
anticancer drug design by leveraging the biomolecular characteristics of
the disease in order to increase success rates in lead compound discovery.
1 Introduction
The last two decades have seen a decline in the productivity of the drug discovery
pipeline while the investment into drug discovery has risen significantly [29].
Indeed, only a minimal portion of drug candidates obtain market approval (less
than 0.01%), with an estimated 10-15 years until market release and costs that
range between one [29] to three billion dollars per drug [30]. This low efficiency
has been attributed to the high dropout rate of candidate molecules in the early
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stages of the pipeline, highlighting the need for more accurate in silico and in
vitro models that produce more successful candidate drugs. Most recently, deep
learning methods have gained popularity within the computational chemistry
community [6] and a number of works have demonstrated the feasibility of in silico
design of novel candidate compounds with desired chemical properties [26,12,40].
In all of these models, the generative process is controlled via a structurally driven
evaluator (or critic) that biases the generation of a chemical to satisfy the required
chemical structural properties. While very effective in generating compounds
with desired chemical properties, these methods do not integrate information
about the cellular environment in which the drug is intended to act. However, the
two main causes of the increasing attrition rate in drug design are lacking efficacy
against the specific disease of interest and off-target cytotoxicity [34], calling
to bridge systems biology closer with drug discovery. In addition to the initial
wet-lab validations, the discovery pipeline involves a sequential process that builds
upon high-throughput screenings, ADMET-assessments (absorption, distribution,
metabolism, excretion and toxicity, i.e., criteria for the pharmacological activity of
a compound) and a lengthy phase of clinical trials. The costs of the experimental
and clinical phase can be prohibitive and any solution that helps to reduce the
number of required experimental assays can provide a competitive advantage
and reduce time to market. To this end, we present a deep RL based model for
anticancer molecule generation that builds on top of the previous approaches
and, for the first time, enables generation of novel anticancer compounds while
taking into account the disease context encoded in the form of gene expression
profile (GEP) of the tumor cell.
The presented framework consists of a conditional molecule generator (embodied
by two separate VAEs) and a critic module that evaluates the efficacy of proposed
compounds on the target profile (see Figure 1). The training procedure splits into
two stages. In the first stage, the models are trained independently; specifically
one VAE is trained on gene expression data from TCGA [36] (see Figure 1A),
another VAE is trained on bioactive small molecules from ChEMBL [2] (see
Figure 1B) and a multimodal drug sensitivity prediction model is fetched from
previous work [20]. In the second stage, the encoder of the profile VAE is combined
with the decoder of the molecule VAE (see Figure 1C)and exposed to a joint
retraining that is optimized in a policy gradient regime with a reward coming
from the critic module (see Figure 1D and E). The goal of the optimization is to
tune the generative model such that it generates (novel) compounds that have
maximal efficacy against a given biomolecular profile; be it the characteristic for
a cancer site, a patient subgroup or even an individual. By efficacy, we refer to
cellular IC50 (i.e. the micromolar concentration necessary to inhibit 50% of the
cells in a sample) as opposed to e.g. enzymatic IC50. It is important to note that
this efficacy is a joint property of a drug-cell-pair and empirically it is well-known
that the efficacy of a compound heavily varies for different types of cells. In
this work, we emphasize profile-specific compound generation and optimize the
generator using IC50 as the sole critic.
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Fig. 1: The proposed framework for anticancer compound design against
specific cancer profiles. A biomolecular profile VAE (PVAE, shown in A) and a
sequential compound generator VAE (SVAE, B) are combined to obtain a conditional
molecule generator (C). Each of the PVAE, SVAE and the predictive critic are pretrained
independently. Thereafter, the conditional generation process starts with a biomolecular
profile of interest e.g., transcriptomic profile from an individual patient. The given
profile is encoded into the latent space of gene expression profiles and is then decoded
through the molecular decoder to produce a candidate compound (D). This generative
process can optionally be “primed” through encoding a known, effective compound
or a functional group with the molecular encoder. Molecules are generated directly as
SMILES sequences which are assembled in a sequential process, one atom at a time. A
full cycle of this process, including the state (st), the reward (Rt) and the candidate
compound (Ct) are shown in (F). The proposed compound is then evaluated through
the critic, a multimodal drug sensitivity prediction model that ingests the compound
and the target profile of interest (E). The RL based optimization is conducted by
maximizing the reward given by the critic. Over the course of training, the generator
will thus learn to produce candidate compounds with higher and higher efficacy.
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2 Methods
Figure 1 shows the two main components of our proposed end-to-end architecture:
the conditional generator (Figure 1D and the critic (Figure 1E).
Conditional generator (G). This is a molecule generator that produces a candidate
drug structure using its SMILES string representation [35]. SMILES sequences
are preferable over (functional) fingerprint-based representations of molecules
(e.g., ECFP [27]) since they have shown to be superior in both predictive [15,20]
and generative models for molecules [4]. In our use case, the generative process
needs to be conditioned on a target biomolecular profile, e.g., from a patient
or a disease. Inspired by [12], we concluded that VAEs are the ideal model for
our task since by design they bring about a structurally ordered latent space
that simplifies the combination of different information sources. Our conditional
generator combines two VAEs that are trained independently prior to being
fused together: 1) a denoising VAE for cancer profile encoding/generation (called
PVAE) and 2) a sequential VAE (SVAE) for SMILES sequence generation. The
detailed derivation and equations for the VAE can be found in [18,31]. PVAE
is pretrained on gene expression profiles (GEP) to learn a consistent latent
representation for biomolecular signatures. SVAE is pretrained on bioactive
drug-like molecules to learn the syntax of valid SMILES and general molecular
semantics. The fact that models that process SMILES sequences must have the
ability to count the ring opening and closing symbols in a molecule necessitates
the use of stack memory [14], in our case implemented through stack-augmented
GRUs as proposed by [16] (the details of the SVAE architecture can be found in
the appendix). Thereafter, the encoder of the PVAE is fused with the decoder
of the SVAE via their latent space. The combination of the two models enables
to learn a latent space that links biomolecular profiles and chemical structures
providing an effective way to sample novel compounds given a specific GEP. In
the final training phase, the weights of the fused model are fine-tuned using a
reward from the critic in a RL framework.
Critic (C). The critic is a multimodal drug sensitivity prediction model which
evaluates the efficacy of any given candidate compound against a biomolecular
profile of interest (e.g., gene expression of a cancer cell line). It outputs a non-
negative reward, a function of the predicted IC50 of the candidate compound for
the target profile, which is used in a RL framework to update the conditional
generator. Following the most recent advances for multimodal drug sensitivity
prediction we herein utilize PaccMann as a critic; specifically convolutional
attention encoders as proposed in [20].
The RL framework. The conditional generator is retrained in combination with
the critic in a RL-based optimization process to tailor molecules towards the
given GEP. First, the GEP is encoded into its latent space, Zc (see Figure 1C).
This embedding is then added to the latent encoding of a primer compound or
substructure (Zp). The advantage of using a primer is that it enables injection
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of prior knowledge into the model by starting the generative process from an
existing and proven effective compound or functional group – instead of designing
a compound from scratch. Formally, the molecule generation is conditioned on a
context Z, where in this work Z = {Zc, Zp}. Since Zc and Zp reflect embeddings
learned from semantically different data sources (gene expression and molecules)
it is non-trivial to combine them meaningfully. We use a summation because
it is a permutation invariant operation and has been proposed in the deep sets
architecture [41] to combine a variable set of unstructured latent encodings.
Our additive latent representation is similar in concept to the conditional VAE
with additive Gaussian encoding space [33]. Intuitively, this fusion presumably
warps the latent space from encoding structural similarity (of molecules or
GEP) into functional similarity [12] so as to aggregate molecules with similar
predicted efficacy for a given cell line. Note that using a primer compound or
substructure is optional and if no priming compound is used, simply the latent
space representation of the <START> token is added to the latent encoding of the
target GEP.
Next, the conditional generator decodes the latent encoding, Zc + Zp, and
generates a molecular structure that, in combination with the GEP, is fed to the
critic to produce a certain reward for the generated compound, as illustrated
in Figure 1D and E. Following the notation of [26], the conditional generator,
G, acts as the agent and the multimodal IC50 prediction model, C, represents
the critic. The weights of C are fixed. We aim to optimize Θ, the parameters
of G, to produce candidate compounds, CT , that target a specific GEP, Xc. In
contrast to [26], we define the set of states S as all possible SMILES strings (with
length ≤ T ) paired with the target GEP. The set of possible actions a that G
can take is a set A, that is a vocabulary of all characters and symbols of the
canonical SMILES language. As depicted in Figure 1F, molecules are generated
by G by sampling an action at at each step(0 < t < T ) from p(at|st−1), where
st−1 = (Ct−1, Xc). Terminal states S∗ ⊂ S are reached when either t = T or
when the terminal action aT = <END> has been sampled. G is trained to learn a
policy, Π(Θ), by maximizing:
Π(Θ) =
∑
sT∈S∗
pΘ(sT )R(sT ) (1)
where the state sT = (CT , Xc) is a tuple of the candidate compound CT and
the cell profile Xc and the reward R(sT ) = f(C(CT , Xc)) is the output of the
critic C scaled by a reward function f . In our experiments, all intermediate
rewards R(st) = 0 where t < T , the sum is approximated using policy gradients,
specifically the REINFORCE algorithm [37] and the reward function f for
determining the reward from the IC50 prediction, C(CT , Xc), is computed by
f(IC50) = exp
(−IC50
α
)
where α = 5 in this work (see details in the appendix).
Data. For the PVAE, we employed a training dataset of 11,592 (normalized)
RNA-Seq GEPs from healthy and cancerous human tissue from the TCGA
database and validated it on 1,289 samples from the same database [36]. The
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number of genes was reduced to the same 2,128 genes as used in [20,21], following
the network propagation procedure described in [22]. The SVAE was pretrained
on the SMILES representation of 1,576,904 compounds (10% were held out for
performance validation) from the ChEMBL database [10]. For RL optimization
of G, we used GEPs publicly available from GDSC [39] and CCLE [1] databases.
Since the RNA-Seq of these cancer cell line databases were passed through
the PVAE (pretrained on human samples from TCGA [36]), we compared the
standardized gene expression distributions for the selected genes across these
databases and found them to be comparable (see appendix). Others also reported
good agreement between transcriptomics data in CCLE and TCGA [11]. Drug
sensitivity data (i.e., IC50) from GDSC and CCLE were used to train the IC50
prediction model, the critic (C). The hyperparameter and details on the utilized
hardware and software can be found in the appendix.
3 Results
3.1 PVAE generation of gene expression profiles
The pretraining results of the PVAE are shown in Figure 2A, B and C. As shown
in Figure 2B, the reconstructed samples (blue plot) as well as the generated
GEPs (green plot) correctly mimic the distribution of the original GEPs (red
plot). Furthermore, the sampled GEPs follow the same lognormal distribution
as the original data. Figure 2C shows that the generated GEPs exhibit a higher
similarity to the testing than to the training sample. Overall, these results suggest
that the pretrained PVAE is able to generate new realistic GEPs of human cells.
3.2 SVAE generation of molecular structures
Figure 2D, E and F give a quantitative analysis of the SVAE results following
pretraining for 10 epochs with ∼1.4 million structures from ChEMBL. For a
qualitative analysis, we provide a sample of molecules in the appendix. Since the
model had a tendency for posterior collapse (relying predominantly on the decoder
[23]), we explored various levels of token dropout for the decoder of SVAE [5]. To
investigate the novelty and diversity of the generated molecules, we sampled 10,000
molecules by decoding random points from the latent space and utilized a well-
established chemical structure similarity measure, the Tanimoto similarity [32] to
compare the ECFP [27] of a subset of 1000 generated molecules with the training
and test data from ChEMBL. Figure 2F presents the distributions of the highest
Tanimoto similarity between each generated compound and all compounds in
training and test dataset respectively. Only a negligible fraction of the generated
molecules existed in either of the datasets, whereas the vast majority had a
Tanimoto similarity (τ) between 0.2 and 0.6 suggesting that our model learned
to propose novel molecular structures from the chemical space of about 1030 to
1060 molecules [24]. Overall, 96.2% of the 10,000 generated molecules were valid
molecular structures (validity assessed via RDKit) surpassing the state of the art
results reported by [26] who used the same stack-augmented GRUs trained on
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Fig. 2: Results of pretrained PVAE and SVAE models. PVAE: (A) Development of
validation error over the course of training. Reconstruction loss (MSE) and KL divergence
are shown separately for comparison. (B) Distribution of gene expression values in
real, reconstructed and generated samples. (C) Sampled (i.e., generated) data from
the latent space of PVAE compared against training and test datasets from TCGA.
SVAE: (D) Development of validation error over the course of training. Cross-entropy
between target and generated SMILES is shown separately from the KL divergence (log
scale for visual clarity). One epoch corresponds to ∼11 000 training steps. (E) The two
losses of our baseline model (keep probability 95%) is compared with a model using
higher a word dropout of 60% (KL loss is scaled by a factor 200 for visual clarity).
Higher word dropout in the decoder increases the encoder loss, i.e., results in storing
more information in the latent space. (F) The Tanimoto similarity between the Morgan
fingerprints (ECFP) of the generated molecules and the structures from ChEMBL
train and test datasets is used to verify that the generated compounds are sufficiently
different from the training data.
the ChEMBL database (95% SMILES validity). In addition, 99.8% of the valid
generated molecules were unique across the 10,000 generations.
3.3 Disease-specific compound generation
Herein, we present the results of our generator conditioned on gene expression
profiles of cancer subtypes. Four different models were trained, one for each of
the cancer sites: breast, lung, prostate and neuroblastoma.
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Fig. 3: Sample results for profile-driven model optimization and anticancer
compound generation. Each row illustrates the results of training the RL pipeline
on cell lines from a specific site: neuroblastoma, breast, lung and prostate cancer. The
first column compares the distributions of IC50 predictions given by the critic model
for a set of n=500 drug candidates generated with RL optimization and without RL
optimization. The second column presents candidate compounds with a high predicted
efficacy (low IC50) against a particular cell line that was not seen during training.
The third column showcases generated compounds that were optimized to be effective
against the average cell-line profiles of the given cancer type in each row. In the fourth
column, we present an existing anticancer compound (approved against at least one
type of cancer), that was in the top-3 neighborhood of the generated compound in
the third column. The existing and generated compounds are compared in terms of
Tanimoto structural similarity as well as three chemical scores crucial in drug design
namely, druglikeness (QED, 0 worst, 1 best), synthesizability (SAS, 1 best, 10 worst)
and solubility (ESOL, given in M/L).
For the evaluation of the four models, all generated compounds with a
predicted IC50 value below 1µM were considered as effective. Moreover, within
each cancer site 80% of the cell lines were considered as training cell lines and used
to optimize the parameters Θ of the conditional generator whereas the remaining
20% were set aside for testing. Our model learned to produce compounds with
lower IC50 values, for unseen cell lines from the given cancer site. The first
PaccMannRL 9
column of Figure 3 shows that the IC50 distribution of candidate compounds
proposed by the generative model were successfully shifted towards higher efficacy.
The baseline model corresponds to the pretrained SVAE from which n = 500
molecules were randomly sampled. In all four cases, a significant portion (between
17% and 30%) of molecules generated from the optimized model were assigned
a IC50 value below 1µM, whereas only 1-4% of the candidates generated by
the baseline model (i.e., the SVAE, a generative model of drug-like molecules
that was not yet optimized via RL retraining) were classified as effective. The
second column of Figure 3 shows generated molecules that are predicted as
being effective against an unseen cell line from the respective cancer site. In
the third column of Figure 3, we showcase novel molecules that were designed
specifically for each cancer site, as opposed to a specific cancer cell profile. All
compounds exhibited high predicted efficacy against the average cellular profile
of the target site while maintaining efficacy against the majority of individual
cell lines for that site. In the last column of Figure 3, we compare the four
site-specific candidate compounds with one of their top-3 neighbors (Tanimoto
similarity, τ) from several hundreds of existing anticancer compounds. The third
closest neighbor of the generated compound against neuroblastoma (Figure 3 first
row, third column) is Fulvestrant, an antagonist/modulator of ERα which has
recently been proposed as a novel anticancer agent for neuroblastoma [13]. The
candidate compound proposed against breast cancer (Figure 3 second row, third
column), has Doxorubicin as one of the top-3 nearest neighbors. Doxorubicin is a
commonly used chemotherapeutical against breast cancer [19]. The generated
compound against lung cancer (Figure 3, third row, third column) results close
to Embelin, an existing anticancer compound from the GDSC database.
Embelin is known to be a promising anticancer compound as it is the only
known non-peptide inhibitor of the XIAP protein [25], a protein that plays an
important role in lung cancer development [7]. Lastly, the closest neighbor of
the prostate-specific generated compound (Figure 3 fourth row, third column)
is Vorapaxar. Its efficacy is highest against a prostate cancer cell line (DU 145)
according to GDSC/CCLE. Vorapaxar is an antagonist of a protease-activated
receptor (PAR-1) that is known to be overexpressed in various types of cancer,
including prostate [42].
4 Discussion
We herein presented the first machine-learning based anti-cancer compound gen-
erator that enables us to condition the molecular generation on the biomolecular
profile (specifically we explored transcriptomic profiles) of the target cell or
cancer site. We demonstrated, using a RL optimization framework, that our
proposed generative model could be optimized to produce candidate compounds
with high predicted efficacy (IC50) against a given target profile. We showcased
in a post-hoc analysis that each of the four site-specific generated compounds
had structural similarities to known anticancer compounds commonly used to
treat cancer of the same type as the generated compound was optimized for.
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Oftentimes however, medical chemists do not start the drug design from scratch,
but from an approved drug and with the goal to find a drug with similar effects
(e.g. increased efficacy or reduced side effects). Our framework neatly grants
the option to incorporate this prior knowledge into the design process already.
Another endeavour is to develop a drug that specifically targets a protein (e.g. one
that has been implicated in tumor proliferation or treatment response according
to a gene-knockout study). Whilst [43] very recently presented a model that
proposed potent DDR1 kinase inhibitors, we are working towards a generic frame-
work where the molecule generation can be conditioned on possibly multimodal
context information such as a target protein, a primed drug, a tumor profile and
notably also a combination thereof by utilising permutation invariant operations
in the multimodal latent space [41]. We have, however, not yet fully explored
the full potential of the framework, e.g. by conditioning the design on a known
drug in conjunction with a cell profile. While we believe our results to be a
promising stepping stone for profile-specific anticancer compound generation, we
are aware further optimization must be done before it can be used a reliable
tool for drug discovery. For instance, there are various other properties of a
candidate drug other than its efficacy that determine its potential for becoming
a successful anticancer compound, for example water solubility, drug-likeness,
synthesizability and cytotoxicity. Our RL optimization framework can easily be
extended with further critics that reward or punish the conditional generator
according to the mentioned properties. For example, water solubility (ESOL [8]),
drug-likeness (QED [3]) and synthesizability (SAS [9]) can all be estimated from
the raw SMILES sequences. In the appendix we compare these properties from
approved drugs in GDSC and CCLE databases to our generated compounds
and find that we do not yet mimick. To that end, we aim to amend the reward
function in the future so as to incorporate rewards not only for efficacy but also
based on other drug-relevant chemical properties.
5 Availability of software and materials
The omics data used to pretrain the PVAE, the molecular data for the SVAE
and the cell profiles used in the RL regime as well as the pretrained mod-
els can be found on https://ibm.box.com/v/paccmann-pytoda-data. To as-
sess the critic, please see [20]. All code to reproduce the experiments is pub-
licly available on https://github.com/PaccMann/. For a detailed example see
https://github.com/PaccMann/paccmann rl.
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5.1 SVAE architecture with StackGRU
To enable neural networks to count, [16] introduced stack-augmented RNN. Stack-
RNNs complement RNNs with a differentiable push-down stack operated through
learnable controllers, opt at step t, that involve three operations: PUSH, POP and
NO-OP (see Figure 4).
opt = s(Wopht), (2)
where ht is the hidden state, Wop is a 3×H matrix (H being the dimension of
hidden state) and s is the softmax function. At each time step the controller
probabilities are determined from Equation 2 and the stack memory is updated
using the learned controller via a multiplicative gating mechanism:

St[0] = opt[PUSH]s(Wsoht) + opt[POP]St−1[1]+
opt[NO-OP]St−1[0]
ht = s(WiXt +WRht−1 +WsiSt−1)
(3)
where St is the stack, Wso is a 1 ×H matrix and Wsi is a H × N matrix (N
being the stack height). Wi is the input matrix applied to the sequence and WR
is the recurrent matrix. It should be noted that for the sake of brevity, we only
show the update equation for the topmost element of the stack in Equation 3.
StackGRU
C N
StackGRU
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σ
Z
Z StackGRU StackGRU StackGRU
C N<START>
C N <END>
B
C
Input OutputHidden
Wi Wo
Operation
S St - 1 t
Xt Yt
S      [0]t - 1 S  [0]t
h t
PUSH POP NO-OP
WopWsi Wso
StackGRUA
 
Fig. 4: (A) The StackGRU architecture adopted in the SVAE. The stack-augmented
GRU (StackGRU) architecture complements a regular GRU with a stack that allows one
out of three possible operations at each time-step: PUSH, POP and NO-OP. The operation
vector is determined through a softmax from the hidden state of each time step.
(B) and (C) are encoder and decoder of the SVAE architecture. (B) encodes the
SMILES sequences into multivariate Gaussians with parameters µ and σ. (C) The
decoder StackGRU units reconstruct the SMILES sequence from a latent representation
(Zp) sampled from the multivariate Gaussian.
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5.2 Reward function
The reward function f(x) = exp (−xα ) was used to map the logarithmic micromolar
IC50 values predicted by the critic to a reward that was subject to maximization
in our adopted RL framework (see Figure 5).
f IC50 exp IC50α
Fig. 5: Reward function to map the predicted IC50 of the critic (PaccMann) to a reward
being fed to the conditional generator. To produce the plot, α was set to 5.
5.3 Gene expression in human samples and cancer cell lines
Comparing the standardized gene expression values of GDSC [39] and CCLE [1]
with the one from human samples from TCGA [36] reveals a similarity (Figure 6).
This justifies our choice of utilizing the encoder of the PVAE for cell line data
during the RL regime, although it was initially pretrained on human samples
from TCGA.
10.0 7.5 5.0 2.5 0.0 2.5 5.0 7.5 10.0
Gene expression
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
De
ns
ity
RNA-Seq distribution of filtered genes
CCLE
TCGA
GDSC
Fig. 6: Distribution of standardized gene expression values across the cancer cell line
databases CCLE [1] and GDSC [39] as well as the human sample database TCGA [36].
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5.4 Implementation and training details
All models were implemented in PyTorch 1.0 and trained on a cluster equipped
with POWER8 processors and a NVIDIA Tesla P100.
PVAE. The model consisted of four dense layers of [1024, 512, 256 and 200] units
with ReLU activation function and dropout of p = 0.2 in both, the encoder and
the decoder. The dimensionality of the latent space (n) was 128. We minimized
the variational loss, consisting of the reconstruction loss and KL divergence, using
Adam optimizer (β1 = 0.9, β2 = 0.999, ε = 1e−8) and a decreasing learning rate
starting at 0.001 [17]. To further regularize the PVAE, denoising methods were
employed by 1) applying a dropout of 0.1 on the input genes and 2) adding noise
to gene expression values (ε ∼ N (0, 0.1)). The model was trained with a batch
size of 64 for a maximum of 2000 epochs.
SVAE. The model was trained on molecules provided in SMILES notation,
the longest molecules had 1423 tokens. Both encoder and decoder consisted of
two layers of bidirectional GRU (hidden size of 128, dropout of 0.1 at the first
layer), each complemented with 50 parallel memory stacks with the depth of 50.
The latent space of SVAE had the same dimensionality as the PVAE (128) to
enable the addition of encodings. Similar optimization parameters as PVAE were
used. This model further utilized teacher forcing [38], i.e., the model’s output
is conditioned on the previous ground truth sample as opposed to its generated
output. Whilst this significantly simplifies learning, it may drive the generator to
predominantly rely on the decoder (thus neglecting the latent encoding). This
so called posterior collapse was resolved by applying a token dropout rate of
0.1 during teacher forcing as suggested by [5]. In addition to token dropout, KL
cost-annealing [5] was employed during training, The model was trained with a
batch size of 128 for a maximum (early stopping) of ∼ 110,000 steps (i.e., exactly
10 epochs) During training, KL cost-annealing as described in [5] was explored
in order to trade-off reconstruction and KL loss.
Critic. The critic was trained using the parameters reported in [20] and replicating
the best performing architecture based on multiscale convolutional encoders.
RL training. In order to maximize Equation 1, we employed Adam optimizer
(β1 = 0.9, β2 = 0.999, ε = 1e−4, weight decay 1e−4) and a decreasing learning
rate starting at 1e−5. The gradients were clipped to 2 to prevent G from destroying
its chemical knowledge about SMILES syntax obtained through pretraining on
ChEMBL. The reward function hyperparameter α was set to 5.
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5.5 SVAE qualitative analysis
Figure 7A, showcases a panel of 12 generated molecules for qualitative assessment
of the molecular structures. The generated molecules generally share drug-like
structural features. To inspect the smoothness of the latent space of molecules,
we encoded a reference molecule shown at the top of Figure 7B into the latent
space and decoded four points in the vicinity of the reference molecule leading to
the generation of structurally similar yet different compounds.
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Fig. 7: Qualitative inspection of generated molecules. (A) A sample of 12 molecular
structures produced with the SVAE. (B) The molecule depicted at the top was encoded
into the latent space. The four molecules below show different decodings from the latent
space in the vicinity of the starting molecule.
5.6 Chemical properties of generated molecules
In this work, the conditional generator is trained using PaccMann as sole critic.
However, besides inhibitory efficacy, there is a myriad of properties of a candidate
drug that crucially influence its potential for becoming an anticancer compound.
Some of these can be approximated in-silico, e.g. water solubility (ESOL [8]),
drug-likeness (QED [3]) and synthesizability (SAS [9]). Figure 8 gives an overview
about the distribution of QED, SAS and ESOL scores for all drugs in GDSC and
CCLE as well as a set of candidate drugs with high predicted efficacy. Comparing
the distributions reveals that our generated molecules do not yet exhibit the same
properties like real anticancer drugs. This is expected, since these scores are not
yet incorporated into the reward function of the generator. It is curious that even
within CCLE database, there is a significant portion of drugs with an estimated
QED < 0.2. Whilst across both databases the average QED is around 0.5, it is
only 0.2 for our molecules. As [28] reported, possessing a certain solubility is a
key property of drugs, with not much deviation being tolerated (Figure 8 middle
panel). In particular regarding the ease of synthesizability (see right panel of
Figure 8), it is evident that further improvement is necessary.
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Fig. 8: Comparison of chemical scores for real drugs in GDSC and CCLE database
versus our generated compounds. We compared three chemical scores for druglikeness
as assessed by QED score (0 worst, 1 best), for solubility as assessed via ESOL, given in
log(M/L) and for synthetic accessibility as assessed by SAS (1 best, 10 worst). These
three scores are computed for all drugs from 1) GDSC database, 2) CCLE database
and 3) a set of generated candidate compounds with high predicted efficacy.
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